文献速递腹部MR

钆塞酸增强MRI的临床与LI-RADS特征预测>2cm肝癌TACE后完全缓解

Clinical and LI-RADS features on gadoxetic acid‑enhanced MRI for predicting complete response after transarterial chemoembolization in hepatocellular carcinoma > 2 cm.
PubMed 文献 · Abdom Radiol (NY) · 2026-07-06

本回顾性单中心研究纳入167例>2cm不可切除肝细胞癌患者,均于首次TACE前2周内行钆塞酸增强MRI。以mRECIST评估TACE后3-4个月的完全缓解,61例(36.5%)达到完全缓解。多因素分析显示肿瘤直径、不规则边界和强化包膜与完全缓解显著相关,三者联合模型AUC为0.723。

要点

  • 肿瘤直径越小、边界规则、存在强化包膜的>2cm HCC患者TACE后更可能达到完全缓解
  • 联合肿瘤直径、不规则边界和强化包膜三项特征的模型AUC为0.723,优于单一特征
  • 不规则边界的存在提示TACE后完全缓解概率降低,报告时应主动描述该征象

核心结论

  • 肿瘤直径、不规则边界和强化包膜是>2cm肝细胞癌患者TACE后完全缓解的独立预测因素
  • 三者联合模型预测完全缓解的AUC为0.723(95%CI:0.649-0.790,p<0.0001),优于各单一预测因素

研究设计与样本

  • 回顾性单中心研究,2018年6月至2025年6月纳入167例不可切除肝细胞癌患者
  • 所有患者均在首次TACE前2周内完成钆塞酸增强MRI检查
  • 治疗反应依据mRECIST分为完全缓解与非完全缓解两类

关键影像表现/征象

  • 不规则边界在钆塞酸增强MRI上表现为肿瘤边缘不光整,与完全缓解呈负相关(OR:0.404,95%CI:0.196-0.832,p=0.014)
  • 强化包膜在钆塞酸增强MRI上表现为肿瘤周边线样强化,与完全缓解呈正相关(OR:3.006,95%CI:1.147-7.877,p=0.025)
  • 肿瘤直径在钆塞酸增强MRI上可精确测量,直径越小完全缓解概率越高(OR:0.965,95%CI:0.943-0.987,p=0.002)

诊断标准与关键数值

  • 肿瘤直径的OR为0.965(95%CI:0.943-0.987,p=0.002),即直径每增加1mm完全缓解概率降低
  • 不规则边界的OR为0.404(95%CI:0.196-0.832,p=0.014)
  • 强化包膜的OR为3.006(95%CI:1.147-7.877,p=0.025)
  • 联合模型AUC为0.723(95%CI:0.649-0.790,p<0.0001)
  • 肿瘤直径、不规则边界、强化包膜单独预测的AUC分别为0.658、0.615和0.565

临床应用与阅片要点

  • TACE前钆塞酸增强MRI报告中应常规描述肿瘤直径、边界是否规则及有无强化包膜
  • 存在强化包膜且边界规则的较小肿瘤更倾向推荐TACE并预期较好反应
  • 存在不规则边界的>2cm HCC预期TACE后完全缓解概率较低,可考虑联合其他治疗策略

局限性

  • 回顾性单中心设计存在选择偏倚和机构依赖性
  • 仅纳入>2cm的肝细胞癌,结果不适用于≤2cm的病灶
  • 完全缓解的评估时点为TACE后3-4个月,未观察长期反应与生存结局

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Transarterial chemoembolization (TACE) is the standard treatment for patients with intermediate-stage hepatocellular carcinoma (HCC), but the rate of complete response (CR) after TACE varies widely. Pretreatment identification of patients likely to achieve CR remains clinically challenging.

PURPOSE: To assess the pretreatment predictive value of liver imaging reporting and data system (LI-RADS) features and clinical features on gadoxetic acid-enhanced MRI (EOB-MRI) for CR after TACE in patients with HCC > 2 cm.

METHODS: From June 2018 to June 2025, 167 patients with unresectable HCC were enrolled in this retrospective single-center study. All patients underwent EOB-MRI within 2 weeks before initial TACE. Treatment response was classified as CR or non-complete response (nCR) using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Clinical and MRI features associated with CR were identified using univariate and multivariate logistic regression analyses. The area under the receiver operating characteristic curve (AUC) was used to assess the model performance.

RESULTS: A total of 61 of the 167 patients (36.5%) achieved CR on follow-up imaging at 3-4 months after TACE. Multivariate analysis revealed that tumor diameter (odds ratio [OR]: 0.965, 95% confidence interval [CI]: 0.943-0.987; p = 0.002), irregular border (OR: 0.404, 95% CI: 0.196-0.832; p = 0.014), and enhancing capsule (OR: 3.006, 95% CI: 1.147-7.877; p = 0.025) were significantly associated with CR. The combined model incorporating these three features yielded an AUC of 0.723 (95% CI: 0.649-0.790, p < 0.0001), outperforming that of each individual predictor (AUC = 0.658, 0.615, and 0.565, respectively).

CONCLUSIONS: A simple imaging-based model incorporating tumor diameter, irregular border, and enhancing capsule achieved moderate performance for predicting CR after TACE in patients with HCC > 2 cm, and may serve as a practical tool for response stratification and individualized treatment decisions.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Liu, Tan, Hu, et al. Clinical and LI-RADS features on gadoxetic acid‑enhanced MRI for predicting complete response after transarterial chemoembolization in hepatocellular carcinoma > 2 cm. Abdom Radiol (NY). 2026. PMID: 42406033. doi:10.1007/s00261-026-05674-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。